StonvexLoading…
StonvexStonvexStonvexCore line items from CLS's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $12.39B | $9.65B | $7.96B | $7.25B |
Operating Income | $1.04B | $599.30M | $338.30M | $289.30M |
Net Income | $832.50M | $428.00M | $244.40M | $180.10M |
EPS (Diluted) | $7.16 | $3.61 | $2.03 | $1.46 |
Total Assets | $7.21B | $5.99B | $5.89B | $5.63B |
Total Liabilities | $5.00B | $4.09B | $4.12B | $3.95B |
Cash & Equivalents | $595.60M | $423.30M | $370.40M | $374.50M |
Free Cash Flow OCF − CapEx | $458.30M | $303.00M | $201.10M | $102.10M |
Shares Outstanding | 114.91M | 116.07M | 120.30M | 123.60M |